News Earnings Suraksha Diagnostic Reports 30.3% Revenue Growth in Q3FY26 with Strong Test Volume ExpansionSuraksha Diagnostic Reports 30.3% Revenue Growth in Q3FY26 with Strong Test Volume Expansion
Suraksha Diagnostic Limited reported strong Q3FY26 results with total income of ₹783.09 million, up 30.3% year-on-year, driven by robust test volume growth of 30.7% to 2.06 million tests. EBITDA increased 26.1% to ₹237.82 million while profit after tax grew 21.0% to ₹72.41 million. The company added 12 new operational centres during the nine-month period and launched its genomics vertical, Suraksha Sutra, strengthening its position as East India's largest integrated diagnostic chain.
*this image is generated using AI for illustrative purposes only.
Suraksha Diagnostic Limited announced strong financial results for the quarter ended December 31, 2025, demonstrating robust growth across key operational and financial metrics. The largest integrated diagnostic chain in East India reported significant expansion in both revenue and test volumes, reflecting the company's successful network expansion strategy.
Financial Performance Highlights
The company delivered impressive financial results for Q3FY26, with total income reaching ₹783.09 million compared to ₹601.12 million in the corresponding quarter of the previous year. This represents a substantial 30.3% year-on-year growth, underlining the company's strong market position and operational efficiency.
| Financial Metric | Q3 FY26 | Q3 FY25 | Growth (%) |
|---|---|---|---|
| Total Income | ₹783.09 million | ₹601.12 million | +30.3% |
| EBITDA | ₹237.82 million | ₹188.55 million | +26.1% |
| Profit After Tax | ₹72.41 million | ₹59.85 million | +21.0% |
| EPS | ₹1.44 | - | - |
EBITDA grew by 26.1% to ₹237.82 million, though the EBITDA margin compressed slightly to 30.6% from 31.7% in the previous year. The company's profit after tax increased by 21.0% to ₹72.41 million, with PAT margin at 9.3% compared to 10.1% in Q3FY25.
Operational Excellence and Volume Growth
The company's operational metrics demonstrated strong performance across all key parameters. Total tests conducted reached 2.06 million, marking a significant 30.7% increase from 1.57 million tests in Q3FY25. The patient base expanded to 0.36 million, representing a 23.0% growth from 0.29 million patients in the corresponding previous quarter.
| Operational Metric | Q3 FY26 | Q3 FY25 | Growth (%) |
|---|---|---|---|
| Total Tests | 2.06 million | 1.57 million | +30.7% |
| Total Patients | 0.36 million | 0.29 million | +23.0% |
| Tests per Patient | 5.77 | 5.43 | +6.2% |
| Average Revenue per Test | ₹378 | ₹378 | -0.1% |
| Average Revenue per Patient | ₹2,181 | ₹2,054 | +6.1% |
The tests per patient metric improved to 5.77 from 5.43, indicating enhanced service utilization. Average revenue per patient increased by 6.1% to ₹2,181, while average revenue per test remained stable at ₹378.
Nine-Month Performance Overview
For the nine-month period ended December 31, 2025, Suraksha Diagnostic maintained strong growth momentum with total income of ₹2,313.81 million, up 21.8% from ₹1,900.27 million in the corresponding period of the previous year. EBITDA for nine months reached ₹734.04 million with a 12.8% growth rate, while profit after tax stood at ₹252.43 million, representing a 6.0% increase.
| Nine-Month Metrics | 9M FY26 | 9M FY25 | Growth (%) |
|---|---|---|---|
| Total Income | ₹2,313.81 million | ₹1,900.27 million | +21.8% |
| EBITDA | ₹734.04 million | ₹650.84 million | +12.8% |
| Profit After Tax | ₹252.43 million | ₹238.07 million | +6.0% |
Strategic Expansion and Market Position
According to Joint Managing Director & CEO Mrs. Ritu Mittal, the company's growth strategy focuses on network expansion and operational excellence. During the nine-month period, Suraksha Diagnostic added 12 fully operational centres with 6 additional centres under development. The company has also launched Suraksha Sutra, its genomics and molecular vertical, establishing a first-mover advantage in the high-value genomics segment in Eastern India.
The company operates as the largest integrated diagnostic chain with presence across West Bengal, Bihar, Assam, and Meghalaya. Its central reference laboratory holds accreditation from the College of American Pathologists, while four laboratories maintain NABL accreditation and three advanced diagnostic centres are NABH accredited.
